OmniAb Inc.
OABI | NASDAQ
$4.58
+$0.11 (+2.46%)
At close: Sep 21, 2026, 4:00 PM ET
$4.60
+$0.02 (+0.44%)
Pre-market:
Sep 22, 2026, 4:00 AM ET
Company Profile
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Key Executives
| Name | Position |
|---|---|
| Matthew W. Foehr | President, Chief Executive Officer & Director |
| Amechi Nwachuku | Executive VP & Chief Operating Officer |
| Charles S. Berkman | Chief Legal Officer |
| Kurt A. Gustafson | Executive Vice President of Finance & Chief Financial Officer |
| Bill Harriman | Senior Vice President of Discovery Partnership Mgt., Technology Development & Operations |
| Bob Chen | Senior Vice President of Discovery Systems |
| Christel Iffland | Senior Vice President of R&D Portfolio Management and Technology Operations |
| Cia McCaffrey | Senior Vice President of People & Talent |
| Todd Pettingill | Vice President of Business Development & Strategy |
| Yasmina Noubia Abdiche | Senior Vice President of Exploratory Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Aug 03, 2026 | 4 | Filing |
| Jul 13, 2026 | 3 | Filing |
| Jul 13, 2026 | 8-K | Current Report |
| Jun 18, 2026 | 4 | Filing |
| Jun 18, 2026 | 4 | Filing |
| Jun 18, 2026 | 4 | Filing |
| Jun 18, 2026 | 4 | Filing |
OmniAb Inc.
| Country | United States |
| IPO Date | Sep 29, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 89 |
| CEO | Matthew W. Foehr |
Contact Details
5980 Horton Street EmeryVille,
California 94608 United States
Stock Details
| Ticker Symbol | OABI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001846253 |
| CUSIP Number | 68218J103 |
| ISIN Number | US68218J1034 |
| SIC Code | 8731 |
Add to Watchlist
Select watchlists to add or remove OABI